Watchman, LAA occluder, atrial fibrillation

The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee voted favorably Dec. 11 in a 13-1 vote that the benefits of the Watchman Left Atrial Appendage Closure (LAA) device outweigh the risks. The company expects a decision from the FDA in the first half of 2014.

Novarad’s NovaCardio electrocardiogram (ECG) integrates with cardiology picture archiving and communication system (PACS)/cardiovascular information system (CVIS) to enable digital ECG reading, annotation, manipulation, storage and easy reporting. NovaCardio ECG was debuted at the Radiological Society of North America Annual Meeting (RSNA 2013) in Chicago.

The National Cheng Kung University Heart Science and Medical Devices Research Center (NCKU HSDMRC) and the Division of Cardiothoracic Surgery, Department of Surgery, Duke University, Durham, NC, USA, jointly carried out a cardiac assist device implantation on a calf in October.

AccessClosure Inc. announced that the U.S. Court of Appeals for the Federal Circuit denied a request by St. Jude Medical Inc. to rehear an appeal on a double patenting ruling concerning its U.S. Patent No. 7,008,439 (the “Janzen ’439 patent"), covering technologies to close holes in arteries.

stony brook JAMA cath lab clinical trial study pharmaceuticals angioplasty

For patients with stable coronary artery disease (CAD) who are not experiencing a heart attack and an abnormal stress test, treatment of their narrowed arteries by the common procedure of angioplasty may not provide additional benefits compared to drug therapy alone.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now